Cell No. : Cell Name
RCB5715 : Y-MESO-72
update : 2024/11/11
|
| Comment | |
| Comment from the depositor | Human malignant pleural mesothelioma cell line. Epithelioid type. |
| Terms and conditions | In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature (Oncogene 2015 34(1):73-83) designated by the DEPOSITOR is requested. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
IPR |
Aichi Cancer Center Research Institute (Japan)
|
| Depositor |
SEKIDO, Yoshitaka
|
| Originator |
SEKIDO, Yoshitaka
|
| Year of deposit |
2022
|
| Cloning (depositor) |
No
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Male
|
| Age at sampling |
63 years
|
| Tissue |
pleural effusion
|
| Primary focus |
malignant pleural mesothelioma
|
| Disease name |
malignant pleural mesothelioma
|
| Tumor |
malignant pleural mesothelioma (cT2N0M0 Stage II iMig)
|
| Metastatic ability |
Unknown
|
| Classification |
cancer
|
| Recombinant |
non-recombinant
|
| Year of origin |
2012
|
|
Lifespan |
infinite
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
Adherent cells
|
Adherent cells
|
| Culture medium |
RPMI1640 + 10% FBS
|
RPMI1640 + 10% FBS
|
| Antibiotics |
1% antimicrobial
|
Free
|
|
Passage method |
0.25w/v% Trypsin + 1mmol/L EDTA (FUJIFILM Solution 209-16941)
|
0.25% Trypsin + (0.02% EDTA or 0.04% EDTA)
|
Culture information
|
Passage ratio |
1/5-1/8
|
1 : 2-4 split
|
| SC frequency |
Subculture : 1-2 times/week
|
Subculture : 1-2 times/week
|
| Temperature |
37
℃
|
37
℃
|
| CO2 concentration |
5
%
|
5
%
|
| Freeze medium |
CELLBANKER
|
CELLBANKER 1
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| Mycoplasma |
(-)
|
|
| Animal PCR |
|
OK
|
| Virus (HIV) |
(-)
|
|
| Virus (HBV) |
(-)
|
|
| Virus (HCV) |
(-)
|
|
| STR(human) |
|
OK
|
|
deposit info
|
| D5S818 |
D13S317 |
D7S820 |
D16S539 |
vWA |
TH01 |
Amelogenin |
TPOX |
CSF1PO |
|
11,12
|
11,14
|
8,12
|
9,12
|
18
|
7,9
|
X,Y
|
8
|
12
|
|
|
lot info
|
| D5S818 |
D13S317 |
D7S820 |
D16S539 |
vWA |
TH01 |
Amelogenin |
TPOX |
CSF1PO |
|
11,12
|
11,14
|
8,12
|
9,12
|
18
|
7,9
|
X,Y
|
8
|
12
|
|
| Reference information |
Reference |
4
|
| User's Publication |
0
|
| Reference |
|
16477
Kato T, Sato T, Yokoi K, Sekido Y.
E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells
Oncogene
2017
36(39):5522-5531
PubMed ID: 28553954
DOI: 10.1038/onc.2017.147
|
|
16026
Kakiuchi T, Takahara T, Kasugai Y, Arita K, Yoshida N, Karube K, Suguro M, Matsuo K, Nakanishi H, Kiyono T, Nakamura S, Osada H, Sekido Y, Seto M, Tsuzuki S.
Modeling mesothelioma utilizing human mesothelial cells reveals involvement of phospholipase-C beta 4 in YAP-active mesothelioma cell proliferation
Carcinogenesis
2016
37(11):1098-1109
PubMed ID: 27559111
DOI: 10.1093/carcin/bgw084
|
|
16468
Hakiri S, Osada H, Ishiguro F, Murakami H, Murakami-Tonami Y, Yokoi K, Sekido Y.
Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells
Cancer Sci
2015
106(8):990-9.
PubMed ID: 26011428
DOI: 10.1111/cas.12698
|
|
16469
Tanaka I, Osada H, Fujii M, Fukatsu A, Hida T, Horio Y, Kondo Y, Sato A, Hasegawa Y, Tsujimura T, Sekido Y.
LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade
Oncogene
2015
34(1):73-83
PubMed ID: 24336325
DOI: 10.1038/onc.2013.528
|
Back
Top
CELL BANK Website